RxDoctor Payments Data

Alexander Mora, MD

Internal Medicine · San Antonio, TXNPI 1225111941

Payments from drug & device makers

$24,117in general payments, 2019–2025

Across 1,090 payments — averaging $22.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$8K
  • AbbVie$2K
  • Supernus Pharmaceuticals, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$971
  • Amgen$914
  • Lilly USA, LLC$797
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$18,056100%
  • Education$540%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca62$7,801
AbbVie(2 entities)203$2,411
Supernus Pharmaceuticals, Inc.55$1,024
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)44$971
Amgen(2 entities)67$914
Lilly USA, LLC47$797
Otsuka America Pharmaceutical, Inc.40$670
Johnson & Johnson22$654
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC40$616
Sunovion Pharmaceuticals Inc.36$512
Bayer29$481
Teva Pharmaceuticals USA, Inc.38$480
Axsome Therapeutics, Inc.19$455
Lundbeck LLC21$402
Merck26$380
Assertio Therapeutics, Inc.52$362
Sanofi-aventis U.S. LLC24$359
Novartis25$334
Esperion Therapeutics, Inc.11$306
Abbott7$275
Almatica Pharma LLC10$263
Pfizer16$256
Novo Nordisk22$249
Azurity Pharmaceuticals, Inc.15$229
Boehringer Ingelheim15$194
Neurocrine Biosciences, Inc.7$181
Vanda Pharmaceuticals Inc.8$177
GSK9$162
Biohaven Pharmaceutical Holding Company Ltd.10$161
Currax Pharmaceuticals LLC11$155
Phathom Pharmaceuticals, Inc.6$118
BD1$109
Takeda Pharmaceuticals U.S.A., Inc.5$105
Scilex Pharmaceuticals Inc.6$95
Sumitomo Pharma America, Inc.5$88
Shield Therapeutics Inc4$86
Amarin Pharma, Inc.4$79
Idorsia Pharmaceuticals US Inc5$79
Exact Sciences3$75
Radius Health, Inc.4$72
Xeris Pharmaceuticals, Inc.4$66
Mannkind Corporation4$65
Cumberland Pharmaceuticals, Inc.4$59
Kowa Pharmaceuticals America, Inc.3$59
OWP Pharmaceuticals, Inc.4$54
Insulet Corporation3$53
Alk-abello, Inc2$51
Nestle Healthcare Nutrition Inc.3$51
Aimmune Therapeutics, Inc.3$49
Biohaven Pharmaceuticals, Inc.2$45
Tris Pharma Inc2$45
E.r. Squibb & Sons, L.L.C.3$45
Bausch Health US, LLC3$40
RGH Enterprises LLC1$39
Ardelyx, Inc.1$34
Aprecia Pharmaceuticals, LLC2$32
SK Life Science, Inc.1$24
Medtronic1$19
Paratek Pharmaceuticals, Inc.1$19
Dexcom, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,117 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$52,626
Medicare patients
60
Services billed
898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide253$285,461
VraylarCariprazine Hcl137$235,078
IngrezzaValbenazine Tosylate27$219,238
OzempicSemaglutide162$175,299
EliquisApixaban116$121,621
LinzessLinaclotide126$105,103
Xigduo XrDapaglifloz Propaned/Metformin126$103,598
Breztri AerosphereBudesonide/Glycopyr/Formoterol95$96,206
TrulicityDulaglutide42$71,298
JardianceEmpagliflozin77$62,067
EntrestoSacubitril/Valsartan34$47,715
FarxigaDapagliflozin Propanediol56$46,745
Tresiba Flextouch U-200Insulin Degludec43$40,412
XareltoRivaroxaban47$39,768
TradjentaLinagliptin35$36,234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Linzess, Qulipta$2,411$356,812278 claims
Lilly USA, LLCMounjaro, Trulicity$797$356,759295 claims
Neurocrine Biosciences, Inc.Ingrezza$181$219,23827 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy, Synjardy Xr, Trijardy Xr$194$175,412194 claims
Novo NordiskOzempic$249$175,299162 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$7,801$154,502184 claims
PfizerEliquis$256$121,621116 claims
MerckJanuvia, Belsomra$380$50,40189 claims
NovartisEntresto$334$47,71534 claims
Johnson & JohnsonXarelto$654$39,76847 claims
GSKTrelegy Ellipta, Breo Ellipta$162$29,96848 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$359$23,19219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →